drugset / Trial / NCT06759298

The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder

NCT06759298

Phase 0 Not yet recruiting 60 enrolled Tanta University
RandomizedParallel-groupOpen-labelHealth-services research

Summary

This study aims to investigate the effects of methylphenidate on symptomatology in individuals with borderline personality disorder. Specifically, it will evaluate whether Concerta is effective in reducing impulsivity, mood instability, and inattention among patients with BPD. Additionally, the study will assess Concerta's safety profile in this population to determine its potential as a supportive pharmacological option in BPD management.

Timeline

Start
2025-01-15
Primary completion
2025-03-25
Completion
2025-03-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 18 mg
Comparator Methylphenidate Small molecule 54 mg